Cue Biopharma, Inc.
Extracted from this filing and checked against the source text.
Cue Biopharma, Inc. shareholders approved Issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement.
The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), (c) and (d), the issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement (“Proposal 1”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,782,133 113,311 1,013 -View on SEC.gov
Cue Biopharma, Inc. shareholders approved Adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2.
The Company’s stockholders approved the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2 (“Proposal 3”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,302,751 582,084 11,622 -View on SEC.gov
Cue Biopharma, Inc. shareholders approved 2026 Plan.
The Company’s stockholders approved the 2026 Plan (“Proposal 2”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,261,296 632,474 2,687 -View on SEC.gov
1591 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.